The first such attempts were made by Soleimani et al. and were focused on the creation of dual-agent protein consisting of p28 and NRC peptides, both characterized by cytotoxic activities with varied mechanisms of action, thus potentially displaying enhanced anti-cancer effects then applied together (Soleimani et al., 2016a; Soleimani et al., 2016b). The gene discussed is NCOA6; the disease is cancer.